The Conflicting Role of Myeloid Cells in CAR T-Cell Therapy
Abstract
Chimeric antigen receptor T (CAR T)-cell therapy is revolutionizing cancer treatment in hematologic malignancies, but challenges related to the tumor microenvironment have hindered CAR T success, especially in solid tumors. Myeloid cells in particular have been implicated in CAR T efficacy. In this review, we discuss the roles of myeloid cells in CAR T-associated toxicities, including cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome, along with strategies to treat these toxicities by modulating myeloid cells. The review also explores myeloid cell-mediated suppression or enhancement of CAR T function. Finally, strategies used to target myeloid cells in combination with CAR T-cell therapy will be investigated.
Fields of Study & Subjects
CAR-T cell therapy research
Cutaneous lymphoproliferative disorders research
Immunotherapy and Immune Responses
Publication details
- Journal / source
- Cancer Research
- Publisher
- American Association for Cancer Research (AACR)
- Volume
- 86
- Issue
- 11
- Pages
- 2581–2591
- Publication date
- 12 March 2026
- Language
- EN